323 related articles for article (PubMed ID: 27040343)
1. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease.
Shama S; Liu W
Dig Dis Sci; 2020 Mar; 65(3):906-910. PubMed ID: 32036510
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
Scorletti E; Byrne CD
Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease.
Musa-Veloso K; Venditti C; Lee HY; Darch M; Floyd S; West S; Simon R
Nutr Rev; 2018 Aug; 76(8):581-602. PubMed ID: 29917092
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
6. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids.
Bouzianas DG; Bouziana SD; Hatzitolios AI
Nutr Rev; 2013 Nov; 71(11):753-71. PubMed ID: 24148001
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
Jump DB; Lytle KA; Depner CM; Tripathy S
Pharmacol Ther; 2018 Jan; 181():108-125. PubMed ID: 28723414
[TBL] [Abstract][Full Text] [Related]
9. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
10. The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice.
Šmíd V; Dvořák K; Stehnová K; Strnad H; Rubert J; Stříteský J; Staňková B; Stránská M; Hajšlová J; Brůha R; Vítek L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139055
[TBL] [Abstract][Full Text] [Related]
11. Associations of serum n-3 and n-6 polyunsaturated fatty acids with prevalence and incidence of nonalcoholic fatty liver disease.
Mäkelä TNK; Tuomainen TP; Hantunen S; Virtanen JK
Am J Clin Nutr; 2022 Sep; 116(3):759-770. PubMed ID: 35648467
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
Scorletti E; Byrne CD
Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
[TBL] [Abstract][Full Text] [Related]
13. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
[TBL] [Abstract][Full Text] [Related]
16. Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.
Enos RT; Velázquez KT; McClellan JL; Cranford TL; Walla MD; Murphy EA
Nutr Res; 2015 May; 35(5):449-59. PubMed ID: 25934114
[TBL] [Abstract][Full Text] [Related]
17. Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome.
Pacifico L; Giansanti S; Gallozzi A; Chiesa C
Mini Rev Med Chem; 2014; 14(10):791-804. PubMed ID: 25307311
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use.
Spooner MH; Jump DB
Annu Rev Nutr; 2023 Aug; 43():199-223. PubMed ID: 37207355
[TBL] [Abstract][Full Text] [Related]
19. [Involvement of the Free Fatty Acid Receptor GPR120/FFAR4 in the Development of Nonalcoholic Steatohepatitis].
Nakamoto K; Tokuyama S
Yakugaku Zasshi; 2019; 139(9):1169-1175. PubMed ID: 31474633
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
Delarue J; Lallès JP
Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
